The entity has a beta of 5.03, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Stemtech will likely underperform. At this point, Stemtech has a negative expected return of -2.86%. Please make sure to validate Stemtech's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Stemtech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Stemtech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in January 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Begin Period Cash Flow
133.1 K
Free Cash Flow
-1.9 M
Stemtech
Stemtech Relative Risk vs. Return Landscape
If you would invest 1.31 in Stemtech on September 25, 2025 and sell it today you would lose (1.19) from holding Stemtech or give up 90.84% of portfolio value over 90 days. Stemtech is currently does not generate positive expected returns and assumes 13.3674% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Stemtech, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Stemtech is expected to under-perform the market. In addition to that, the company is 18.75 times more volatile than its market benchmark. It trades about -0.21 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.
Stemtech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stemtech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Stemtech, and traders can use it to determine the average amount a Stemtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2136
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
STEK
Based on monthly moving average Stemtech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Stemtech by adding Stemtech to a well-diversified portfolio.
Stemtech Fundamentals Growth
Stemtech OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Stemtech, and Stemtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stemtech OTC Stock performance.
By examining Stemtech's fundamental ratios, stakeholders can obtain critical insights into Stemtech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Stemtech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Things to note about Stemtech performance evaluation
Checking the ongoing alerts about Stemtech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Stemtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Stemtech generated a negative expected return over the last 90 days
Stemtech has some characteristics of a very speculative penny stock
Stemtech currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M.
Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 64.0% of the company outstanding shares are owned by corporate insiders
Evaluating Stemtech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Stemtech's otc stock performance include:
Analyzing Stemtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stemtech's stock is overvalued or undervalued compared to its peers.
Examining Stemtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Stemtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stemtech's management team can help you assess the OTC Stock's leadership.
Pay attention to analyst opinions and ratings of Stemtech's otc stock. These opinions can provide insight into Stemtech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Stemtech's otc stock performance is not an exact science, and many factors can impact Stemtech's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.